



Universiteit
Leiden
The Netherlands

Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome

Chen, L.

Citation

Chen, L. (2023, December 19). *Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome*. Retrieved from <https://hdl.handle.net/1887/3674169>

Version: Publisher's Version

[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

License: <https://hdl.handle.net/1887/3674169>

Note: To cite this publication please use the final published version (if applicable).

Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome

Printing of this thesis was financially supported by Certara

Cover design: Lu Chen and DALL·E 2

Thesis lay-out: Lu Chen

Printing: Ridderprint BV

© Copyright, Lu Chen, 2023

ISBN: 978-94-6483-565-6

All rights reserved. No part of this book may be reproduced in any form or by any means without permission of the author.

Optimizing antifungal treatment through pharmacometrics: dosing considerations to enhance outcome

Proefschrift

ter verkrijging van de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 19 december 2023

klokke 12.30 uur

door

Lu Chen

geboren te Yan'an, China

in 1993

Promotor:

Prof. dr. C.A.J. Knibbe

Co-promotores:

Dr. E.H.J. Krekels

Dr. R.J. Brüggemann (Radboudumc)

Promotiecommissie:

Prof. dr. H. Irth

Prof. dr. E.C.M. de Lange

Dr. E.M. Svensson (Uppsala University)

Dr. J.G.C. van Hasselt

Prof. dr. P.E. Verweij (Radboudumc)

The research described in this thesis was performed at the division Systems Pharmacology and Pharmacy of the Leiden Academic Centre for Drug Research (LACDR), Leiden University (Leiden, The Netherlands). The research was financially supported by the China Scholarship Council (CSC).

Contents

Section I	Background and introduction	
<hr/>		
Chapter 1	General introduction and scope	7
Chapter 2	Pharmacokinetics and Pharmacodynamics of Posaconazole	17
Section II	Difference in posaconazole pharmacokinetics: formulation and population	
<hr/>		
Chapter 3	An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers	53
Chapter 4	Meta-PK analysis of posaconazole upon dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race	75
Section III	Fluconazole dose advice in obese adults	
<hr/>		
Chapter 5	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults	97
Chapter 6	Summary, lessons learned, perspectives, and overall conclusions	119
	Nederlandse samenvatting	133
Appendices	List of publications	136
	Curriculum vitae	137
	Acknowledgments	138